OBJECTIVE: To rapidly evaluate the efficacy

safety and economical efficiency of Shengmai injection in the treatment of cardiac failure based on rapid health technology assessment（HTA）

so as to provide evidence-based evidence for clinical rational drug use. METHODS: Wanfang Data

CNKI

CBM

the Cochrane Library

Embase

PubMed and HTA organization websites（HTAi and INAHTA） were searched systematically

HTA reports

systematic reviews/Meta-analysis and pharmacoeconomic studies of Shengmai injection in the treatment of heart failure were included. The included data were summarized and analyzed

and the quality of literature and methodology was evaluated. RESULTS: A total of 12 literature were included

including 9 systematic reviews/Meta-analysis and 3 pharmacoeconomic studies

yet no HTA report was retrieved. The results show that Shengmai injection combination with western medicine in the treatment of cardiac failure can improve the total effective rate

increase the left ventricular ejection fraction（LVEF）

6 min walking test distance

cardiac output

stroke volume

improve New York Heart Association cardiac function classification

Minnesota heart failure quality of life scale score and cardiac index

reduce the N-terminal pro-B-type natriuretic peptide level

left ventricular end-diastolic diameter. In terms of improving the short-axis shortening rate of the left ventricle and reducing the level of brain natriuretic peptide

the conclusions of various studies were inconsistent. Meanwhile

the incidence of adverse drug reactions of Shengmai injection was similar to that of the control regimen. CONCLUSIONS: Shengmai injection can effectively improve the clinical symptoms of heart failure. In the future

more in-depth pharmacoeconomic studies and more standardized clinical observation and safety evaluation of the drug can be carried out to supplement relevant evidence-based evidence for medication.